Optimal size of DNA encapsidated by plant produced human papillomavirus pseudovirions
- PMID: 36801669
- DOI: 10.1016/j.virol.2023.02.003
Optimal size of DNA encapsidated by plant produced human papillomavirus pseudovirions
Abstract
Human papillomaviruses (HPVs) are known to be the cause of anogenital and oropharyngeal cancers as well as genital and common warts. HPV pseudovirions (PsVs) are synthetic viral particles that are made up of the L1 major and L2 minor HPV capsid proteins and up to 8 Kb of encapsidated pseudogenome dsDNA. HPV PsVs are used to test novel neutralising antibodies elicited by vaccines, for studying the virus life cycle, and potentially for the delivery of therapeutic DNA vaccines. HPV PsVs are typically produced in mammalian cells, however, it has recently been shown that Papillomavirus PsVs can be produced in plants, a potentially safer, cheaper and more easily scalable means of production. We analysed the encapsidation frequencies of pseudogenomes expressing EGFP, ranging in size from 4.8 Kb to 7.8 Kb, by plant-made HPV-35 L1/L2 particles. The smaller pseudogenomes were found to be packaged more efficiently into PsVs as higher concentrations of encapsidated DNA and higher levels of EGFP expression were obtained with the 4.8 Kb pseudogenome, compared to the larger 5.8-7.8 Kb pseudogenomes. Thus, smaller pseudogenomes, of 4.8 Kb, should be used for efficient plant production of HPV-35 PsVs.
Keywords: Biopharming; DNA size; HPV; Plant-made; Pseudogenome; Pseudovirions; Vaccine.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Inga Isabel Hitzeroth and Edward P Rybicki hold a patent on plant made PsVs.
Similar articles
-
Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.Sci Rep. 2016 Feb 8;6:20431. doi: 10.1038/srep20431. Sci Rep. 2016. PMID: 26853456 Free PMC article.
-
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15. J Virol. 2016. PMID: 27147749 Free PMC article.
-
Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry.J Virol. 2019 Jun 14;93(13):e00128-19. doi: 10.1128/JVI.00128-19. Print 2019 Jul 1. J Virol. 2019. PMID: 30996086 Free PMC article.
-
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018. Viruses. 2019. PMID: 31877975 Free PMC article. Review.
-
Developments in L2-based human papillomavirus (HPV) vaccines.Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Virus Res. 2017. PMID: 27889616 Free PMC article. Review.
Cited by
-
Development of an African horse sickness VP6 DIVA diagnostic ELISA.Virol J. 2025 Aug 12;22(1):276. doi: 10.1186/s12985-025-02898-1. Virol J. 2025. PMID: 40796889 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources